Market Cap 365.01M
Revenue (ttm) 0.00
Net Income (ttm) -236.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.75
Volume 829,200
Avg Vol 1,313,022
Day's Range N/A - N/A
Shares Out 185.28M
Stochastic %K 15%
Beta 3.02
Analysts Sell
Price Target $9.14

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associ...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 760 0900
Address:
260 Arsenal Place, Suite 1, Watertown, United States
Kaltycoon
Kaltycoon May. 16 at 2:17 AM
$NMRA this FDA shake up isn’t doing us good, let’s get back n track ASAP and fast track promising tech
0 · Reply
btown_moneymike
btown_moneymike May. 15 at 4:52 AM
$NMRA 🥱 wen $10
1 · Reply
Kaltycoon
Kaltycoon May. 14 at 8:06 PM
$NMRA nice price action today, all the gamblers loading up into readouts. This is the year of biotech! Might as well get lucky.
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW May. 14 at 7:56 PM
$NMRA only a few mil diluted last 6 weeks, this rerates price violently imo, options telling you what's coming...
0 · Reply
Kaltycoon
Kaltycoon May. 14 at 1:55 PM
$NMRA all right $BIIB we see you, we got our own stuff developing. Some validation if they believe they can advance the trial despite setbacks. https://investors.biogen.com/news-releases/news-release-details/topline-results-phase-2-celia-study-diranersen-biib080-first
0 · Reply
Kaltycoon
Kaltycoon May. 14 at 1:52 PM
$NMRA someone loaded big in those low prices yesterday
0 · Reply
Kaltycoon
Kaltycoon May. 13 at 11:18 PM
$NMRA retail investors bashing this ticker but all I see is smart money loading, likes of Vanguards, Blackrocks and Chase and early investors aren’t moving away just yet. Fidelity and others will be back soon to average down on remaining positions.
0 · Reply
Kaltycoon
Kaltycoon May. 13 at 8:32 PM
$NMRA where in the last year I’ve cought two spikes on this, now it’s positioned like a gamble play. Extremely binary situation going into summer.
0 · Reply
Xmandingo
Xmandingo May. 13 at 6:13 PM
$NMRA big dumpster fire here… SMH
1 · Reply
ute16
ute16 May. 13 at 12:39 PM
$NMRA waiting...for 5$
0 · Reply
Latest News on NMRA
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)

2026-05-07T15:39:57.000Z - 8 days ago

Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)


Neumora Therapeutics management to meet with Piper Sandler

2026-04-02T14:37:16.000Z - 6 weeks ago

Neumora Therapeutics management to meet with Piper Sandler


Neumora Therapeutics Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

Neumora Therapeutics Earnings Call Transcript: Q4 2025


Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)

2026-03-30T11:00:07.000Z - 6 weeks ago

Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)


Neumora Therapeutics management to meet virtually with Needham

2026-03-02T18:05:39.000Z - 2 months ago

Neumora Therapeutics management to meet virtually with Needham


Neumora Therapeutics initiated with an Outperform at Leerink

2026-01-12T10:25:32.000Z - 4 months ago

Neumora Therapeutics initiated with an Outperform at Leerink


Neumora Therapeutics Transcript: Study Result

Jan 5, 2026, 8:00 AM EST - 4 months ago

Neumora Therapeutics Transcript: Study Result


Neumora Therapeutics highlights 2026 pipeline strategy

2026-01-05T11:41:35.000Z - 4 months ago

Neumora Therapeutics highlights 2026 pipeline strategy


LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

2025-11-12T13:15:37.000Z - 6 months ago

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

LBRX


Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)

2025-11-06T12:06:36.000Z - 6 months ago

Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)


Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim

2025-10-27T12:06:02.000Z - 7 months ago

Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim


Neumora Therapeutics Transcript: R&D Day 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Neumora Therapeutics Transcript: R&D Day 2025


Neumora Therapeutics’ NMRA-215 shows weight loss efficacy

2025-10-27T10:40:05.000Z - 7 months ago

Neumora Therapeutics’ NMRA-215 shows weight loss efficacy


Neumora Therapeutics to Host Virtual R&D Day on October 27

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27


Neumora Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Neumora Therapeutics Earnings Call Transcript: Q2 2025


Neumora Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q1 2025


Neumora Therapeutics Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q4 2024


Kaltycoon
Kaltycoon May. 16 at 2:17 AM
$NMRA this FDA shake up isn’t doing us good, let’s get back n track ASAP and fast track promising tech
0 · Reply
btown_moneymike
btown_moneymike May. 15 at 4:52 AM
$NMRA 🥱 wen $10
1 · Reply
Kaltycoon
Kaltycoon May. 14 at 8:06 PM
$NMRA nice price action today, all the gamblers loading up into readouts. This is the year of biotech! Might as well get lucky.
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW May. 14 at 7:56 PM
$NMRA only a few mil diluted last 6 weeks, this rerates price violently imo, options telling you what's coming...
0 · Reply
Kaltycoon
Kaltycoon May. 14 at 1:55 PM
$NMRA all right $BIIB we see you, we got our own stuff developing. Some validation if they believe they can advance the trial despite setbacks. https://investors.biogen.com/news-releases/news-release-details/topline-results-phase-2-celia-study-diranersen-biib080-first
0 · Reply
Kaltycoon
Kaltycoon May. 14 at 1:52 PM
$NMRA someone loaded big in those low prices yesterday
0 · Reply
Kaltycoon
Kaltycoon May. 13 at 11:18 PM
$NMRA retail investors bashing this ticker but all I see is smart money loading, likes of Vanguards, Blackrocks and Chase and early investors aren’t moving away just yet. Fidelity and others will be back soon to average down on remaining positions.
0 · Reply
Kaltycoon
Kaltycoon May. 13 at 8:32 PM
$NMRA where in the last year I’ve cought two spikes on this, now it’s positioned like a gamble play. Extremely binary situation going into summer.
0 · Reply
Xmandingo
Xmandingo May. 13 at 6:13 PM
$NMRA big dumpster fire here… SMH
1 · Reply
ute16
ute16 May. 13 at 12:39 PM
$NMRA waiting...for 5$
0 · Reply
GangsterX
GangsterX May. 12 at 6:15 PM
$CHRS $NMRA small bet couple weeks ago and still holding
0 · Reply
Kaltycoon
Kaltycoon May. 12 at 6:15 PM
$LCTX $NMRA tanked 25% on slight beat and no updates, just saying as I’m invested in both
0 · Reply
Kaltycoon
Kaltycoon May. 11 at 1:16 PM
0 · Reply
Kaltycoon
Kaltycoon May. 9 at 7:30 AM
$NMRA wonder when this transaction happened timeline
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW May. 8 at 7:36 PM
$NMRA options flow has spoken, slap that ask if you want in, this is the way….
0 · Reply
Kaltycoon
Kaltycoon May. 8 at 7:16 PM
$NMRA someone made a swing short here, also bunch of people got stopped out:
0 · Reply
Only_Bulls
Only_Bulls May. 8 at 6:48 PM
$NMRA increased my position by 20% today! Let’s Goooo! Thanks for the cheapies!
0 · Reply
Kaltycoon
Kaltycoon May. 8 at 3:54 PM
$NMRA latest 10Qs are transparent, just need better and cleaner updates on trials with peer reviews. Where there is risk, there is reward.
0 · Reply
Kaltycoon
Kaltycoon May. 8 at 2:45 PM
$NMRA $MRNA the only way is up, the year of biotech
2 · Reply
InvestorCG
InvestorCG May. 8 at 2:27 PM
$NMRA These are the times that try mans souls.
0 · Reply
Kaltycoon
Kaltycoon May. 7 at 10:40 PM
$NMRA most biotech is down today, readouts not too good, can Neumora be in the 10% that succeeds?!
0 · Reply
InvestorCG
InvestorCG May. 7 at 8:27 PM
$NMRA 10 Q is out. K2 converted most if not all of their .87 share conversions, but still has their $2.30+ ones left. Ha, underwater. F them. What is more concerning to me is D-bag management hit the ATM already in 2026. Diluting still in the $2 range.....SHAME SHAME SHAME ON YOU GUYS. "During the three months ended March 31, 2026, we received aggregate net proceeds of $10.9 million through sales of shares of our common stock under the ATM after deducting commissions and offering expenses."
1 · Reply